Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (NCT06380751)
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Who can join: Review the eligibility criteria below.
Location: Research Site — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (302 Sites)
Showing the first 25 of 302 sites.
- Research Site — Gilbert, Arizona
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
- Research Site — Los Angeles, California
- Research Site — Newport Beach, California
- Research Site — Aurora, Colorado
- Research Site — Grand Junction, Colorado
- Research Site — Hollywood, Florida
- Research Site — Jacksonville, Florida
- Research Site — Orlando, Florida
- Research Site — Arlington Heights, Illinois
- Research Site — Chicago, Illinois
- Research Site — Evanston, Illinois
- Research Site — Park Ridge, Illinois
- Research Site — Urbana, Illinois
- Research Site — Winfield, Illinois
- Research Site — Indianapolis, Indiana
- Research Site — Louisville, Kentucky
- Research Site — Baltimore, Maryland
- Research Site — Silver Spring, Maryland
- Research Site — Silver Spring, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Dearborn, Michigan
- Research Site — Detroit, Michigan
- Research Site — Royal Oak, Michigan
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Breast Cancer
- RCT of CBD for Anxiety in Advanced Breast Cancer — Boston, Massachusetts
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Encinitas, California
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Springdale, Arkansas
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer — St Louis, Missouri
- Engage Psychosocial Intervention for Cancer Symptoms — Durham, North Carolina
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — Duarte, California
Explore by condition: All Advanced Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.